Understanding how SHP2 and BCL2 inhibitors work in treating Acute Myeloid Leukemia
Investigating the mechanism of SHP2 and BCL2 Inhibition in Acute Myeloid Leukemia (AML)
This study is looking at how two new types of medicines might help people with Acute Myeloid Leukemia (AML) who have certain genetic changes and haven't responded well to other treatments, with the goal of finding better ways to tailor therapies just for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10879172 on NIH RePORTER |
What this research studies
This research investigates the role of SHP2 and BCL2 inhibitors in treating Acute Myeloid Leukemia (AML), particularly focusing on patients with specific genetic mutations. The study aims to understand how these inhibitors can work together to improve treatment outcomes for patients who have developed resistance to existing therapies. By using advanced techniques like single-cell multiomic sequencing, researchers will identify biomarkers that predict how well patients respond to these treatments. This approach could lead to more personalized and effective therapies for AML patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with Acute Myeloid Leukemia, especially those with FLT3 or KIT mutations.
Not a fit: Patients with other types of leukemia or those who do not have the specific mutations targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with Acute Myeloid Leukemia, particularly those who have not responded to current therapies.
How similar studies have performed: Previous research has shown promising results using similar approaches with targeted therapies in other cancers, indicating potential for success in this area as well.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Smith, Catherine Choy — University of California, San Francisco
- Study coordinator: Smith, Catherine Choy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.